Browsing Clinical Studies by author "Dearnaley, David"
Now showing items 21-40 of 43
-
Increased Dose to Organs in Urinary Tract Associates With Measures of Genitourinary Toxicity in Pooled Voxel-Based Analysis of 3 Randomized Phase III Trials.
Marcello, M; Denham, JW; Kennedy, A; Haworth, A; Steigler, A; et al. (FRONTIERS MEDIA SA, 2020-07-22)Purpose: Dose information from organ sub-regions has been shown to be more predictive of genitourinary toxicity than whole organ dose volume histogram information. This study aimed to identify anatomically-localized regions ... -
Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients.
Andreassen, CN; Rosenstein, BS; Kerns, SL; Ostrer, H; De Ruysscher, D; et al. (ELSEVIER IRELAND LTD, 2016-12-01)PURPOSE: Several small studies have indicated that the ATM rs1801516 SNP is associated with risk of normal tissue toxicity after radiotherapy. However, the findings have not been consistent. In order to test this SNP in a ... -
Ki67 Is an Independent Predictor of Recurrence in the Largest Randomized Trial of 3 Radiation Fractionation Schedules in Localized Prostate Cancer.
Wilkins, AC; Gusterson, B; Szijgyarto, Z; Haviland, J; Griffin, C; et al. (ELSEVIER SCIENCE INC, 2018-06-01)PURPOSE: To assess whether the cellular proliferation marker Ki67 provides prognostic information and predicts response to radiation therapy fractionation in patients with localized prostate tumors participating in a ... -
Large-scale meta-genome-wide association study reveals common genetic factors linked to radiation-induced acute toxicities across cancer types.
Naderi, E; Aguado-Barrera, ME; Schack, LMH; Dorling, L; Rattay, T; et al. (OXFORD UNIV PRESS, 2023-10-31)BACKGROUND: This study was designed to identify common genetic susceptibility and shared genetic variants associated with acute radiation-induced toxicity across 4 cancer types (prostate, head and neck, breast, and lung). ... -
Linkage of the CHHiP randomised controlled trial with primary care data: a study investigating ways of supplementing cancer trials and improving evidence-based practice.
Lemanska, A; Byford, RC; Cruickshank, C; Dearnaley, DP; Ferreira, F; et al. (BMC, 2020-07-25)BACKGROUND: Randomised controlled trials (RCTs) are the gold standard for evidence-based practice. However, RCTs can have limitations. For example, translation of findings into practice can be limited by design features, ... -
Linking CHHiP prostate cancer RCT with GP records: A study proposal to investigate the effect of co-morbidities and medications on long-term symptoms and radiotherapy-related toxicity.
Lemanska, A; Byford, RC; Correa, A; Cruickshank, C; Dearnaley, DP; et al. (Elsevier BV, 2017-06-27)BACKGROUND: Patients receiving cancer treatment often have one or more co-morbid conditions that are treated pharmacologically. Co-morbidities are recorded in clinical trials usually only at baseline. However, co-morbidities ... -
Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN).
Ma, TM; Chu, F-I; Sandler, H; Feng, FY; Efstathiou, JA; et al. (ELSEVIER, 2022-10-14)CONTEXT: The prognostic importance of local failure after definitive radiotherapy (RT) in National Comprehensive Cancer Network intermediate- and high-risk prostate cancer (PCa) patients remains unclear. OBJECTIVE: To ... -
Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer.
Kerns, SL; Dorling, L; Fachal, L; Bentzen, S; Pharoah, PDP; et al. (ELSEVIER, 2016-08-01)Nearly 50% of cancer patients undergo radiotherapy. Late radiotherapy toxicity affects quality-of-life in long-term cancer survivors and risk of side-effects in a minority limits doses prescribed to the majority of patients. ... -
Multi-candidate immunohistochemical markers to assess radiation response and prognosis in prostate cancer: results from the CHHiP trial of radiotherapy fractionation.
Wilkins, A; Gusterson, B; Tovey, H; Griffin, C; Stuttle, C; et al. (ELSEVIER, 2023-02-01)BACKGROUND: Protein markers of cellular proliferation, hypoxia, apoptosis, cell cycle checkpoints, growth factor signalling and inflammation in localised prostate tumours have previously shown prognostic ability. A ... -
Neutrophil to Lymphocyte Ratio in Castration-Resistant Prostate Cancer Patients Treated With Daily Oral Corticosteroids.
Mehra, N; Sharp, A; Lorente, D; Dolling, D; Sumanasuriya, S; et al. (CIG MEDIA GROUP, LP, 2017-12-01)BACKGROUND: The neutrophil to lymphocyte ratio (NLR) has been shown to be highly prognostic across many tumor types, and predictive of treatment outcome in advanced prostate cancer, and has been postulated to be an indirect ... -
Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) Analogs in Combination With Radiation Therapy in the CHHiP Trial.
Tree, A; Griffin, C; Syndikus, I; Birtle, A; Choudhury, A; et al. (ELSEVIER SCIENCE INC, 2022-06-01)PURPOSE: CHHiP is a randomized trial evaluating moderately hypofractionated radiation therapy for treatment of localized prostate cancer. Of all participants, 97% of them had concurrent short-course hormone therapy (HT), ... -
Observation versus screening spinal MRI and pre-emptive treatment for spinal cord compression in patients with castration-resistant prostate cancer and spinal metastases in the UK (PROMPTS): an open-label, randomised, controlled, phase 3 trial.
Dearnaley, D; Hinder, V; Hijab, A; Horan, G; Srihari, N; et al. (ELSEVIER SCIENCE INC, 2022-03-10)BACKGROUND: Early diagnosis of malignant spinal cord compression (SCC) is crucial because pretreatment neurological status is the major determinant of outcome. In metastatic castration-resistant prostate cancer, SCC is a ... -
Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer.
Rescigno, P; Lorente, D; Bianchini, D; Ferraldeschi, R; Kolinsky, MP; et al. (ELSEVIER SCIENCE BV, 2016-11-01)BACKGROUND: The availability of multiple new treatments for metastatic castration-resistant prostate cancer (mCRPC) mandates earlier treatment switches in the absence of a response. A decline in prostate-specific antigen ... -
Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy.
Kerns, SL; Fachal, L; Dorling, L; Barnett, GC; Baran, A; et al. (OXFORD UNIV PRESS INC, 2020-02-01)BACKGROUND: A total of 10%-20% of patients develop long-term toxicity following radiotherapy for prostate cancer. Identification of common genetic variants associated with susceptibility to radiotoxicity might improve risk ... -
Radiotherapy Quality Assurance for the CHHiP Trial: Conventional Versus Hypofractionated High-Dose Intensity-Modulated Radiotherapy in Prostate Cancer.
Naismith, O; Mayles, H; Bidmead, M; Clark, CH; Gulliford, S; et al. (ELSEVIER SCIENCE LONDON, 2019-09)AIMS: The CHHiP trial investigated the use of moderate hypofractionation for the treatment of localised prostate cancer using intensity-modulated radiotherapy (IMRT). A radiotherapy quality assurance programme was developed ... -
Reduced Dose Posterior to Prostate Correlates With Increased PSA Progression in Voxel-Based Analysis of 3 Randomized Phase 3 Trials.
Marcello, M; Denham, JW; Kennedy, A; Haworth, A; Steigler, A; et al. (ELSEVIER SCIENCE INC, 2020-12-01)PURPOSE: Reducing margins during treatment planning to decrease dose to healthy organs surrounding the prostate can risk inadequate treatment of subclinical disease. This study aimed to investigate whether lack of dose to ... -
Relationships between rectal and perirectal doses and rectal bleeding or tenesmus in pooled voxel-based analysis of 3 randomised phase III trials.
Marcello, M; Denham, JW; Kennedy, A; Haworth, A; Steigler, A; et al. (ELSEVIER IRELAND LTD, 2020-09-01)BACKGROUND AND PURPOSE: This study aimed to identify anatomically-localised regions where planned radiotherapy dose is associated with gastrointestinal toxicities in healthy tissues throughout the pelvic anatomy. MATERIALS ... -
Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials.
Ma, TM; Sun, Y; Malone, S; Roach, M; Dearnaley, D; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2023-02-01)PURPOSE: The sequencing of androgen-deprivation therapy (ADT) with radiotherapy (RT) may affect outcomes for prostate cancer in an RT-field size-dependent manner. Herein, we investigate the impact of ADT sequencing for men ... -
Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era'': Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)
James, ND; Spears, MR; Clarke, NW; Dearnaley, DP; De Bono, JS; et al. (Elsevier BV, 2015-06-01) -
The Efficacy and Safety of Conventional and Hypofractionated High-Dose Radiation Therapy for Prostate Cancer in an Elderly Population: A Subgroup Analysis of the CHHiP Trial.
Wilson, JM; Dearnaley, DP; Syndikus, I; Khoo, V; Birtle, A; et al. (ELSEVIER SCIENCE INC, 2018-04-01)PURPOSE: Outcome data on radiation therapy for prostate cancer in an elderly population are sparse. The CHHiP (Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy in Prostate Cancer) trial provides ...